Transparency Market Research
Joint pain is the most common disorder affecting the population over 60 years of age. Over 50 million people in the U.S. currently suffer from arthritis, according to the Arthritis Foundation. If patients continue to experience joint pain, discomfort, or swelling in the joints for a period of time, physicians recommend injections to suppress the pain or surgery. A variety of joint injections is available to alleviate the pain associated with conditions such as arthritis or joint injury. Generally, a joint pain injection is recommended by physicians for those who do not respond to alternative treatments such as oral medications (anti-inflammatory) or physical therapy. Physicians who administer joint injections include physiatrists (PM&R), anesthesiologists, radiologists, neurologists, and surgeons.
Rise in prevalence of osteoarthritis among the population, green signal by regulatory authorities for the launch of novel injectable therapies for joint pain, and preference of physicians for injection therapy before recommending surgical procedures are few of the factors expected to drive the global joint pain injection market in the coming years. However, unpredictability about the duration of the effects of injections on the joints and patient discomfort during the injection procedure are anticipated to be the key restraints of the global joint pain injection market in the coming years.
The global joint pain injection market can be segmented based on joint, injection, application, function, distribution channel, and region. Based on joint, the global joint pain injection market can be categorized into facet joints of the spine, hip joint, shoulder & elbow, knee & ankle, sacroiliac joint, and others. The knee & ankle segment accounted for a significant market share in terms of revenue in 2017. This was attributable to the launch of novel knee joint pain injections by key manufacturers and rise in incidence of knee injuries and pain across the globe. The segment is expected to continue to remain dominant throughout the forecast period. In terms of injection, the global joint pain injection market can be classified into hyaluronic acid injection, corticosteroid injection, platelets-rich plasma (PRP) injection, and stem cells injection. The corticosteroid segment accounted for a major portion of revenue in 2017, owing to the high efficacy and potency of corticosteroid injections and their significant duration of action, which is a few years. However, due to side effects associated with the use of corticosteroids for joint pain, such as temporary weight gain and water retention in the body, physicians have started preferring hyaluronic acid. This is expected to propel the hyaluronic acid segment during the forecast period.
Based on application, the global joint pain injection market can be segmented into joint injury, arthritis, degeneration of tissues, and others. Arthritis was a key segment in terms of revenue in 2017 and is anticipated to continue to lead throughout the forecast period. In terms of function, the joint pain injection market can be divided into diagnostic and pain relief. The pain relief segment is expected to lead the market during the forecast period due to rise in demand for injections providing long-term pain relief, especially for the knee joints. Based on distribution channel, the global joint pain injection market can be classified into hospital pharmacy, retail pharmacy, and online pharmacy. The hospital pharmacy segment constituted a prominent market share in 2017 owing to the availability of well-qualified health care professionals such as anesthesiologist, surgeons, physiatrists, neurologists, and radiologists under one roof in hospitals. However, a shift in preference of the population toward e-commerce websites for the purchase of medications is expected to propel the online channel segment in the near future.
In terms of region, the global joint pain injection market can be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Strategic presence of prominent manufacturers in the U.S. and Canada and U.S. FDA approval of novel injectable therapies for joint pain were the key factors for the dominance of North America in 2017. Europe was a prominent region of the market in 2017. However, the market in Asia Pacific is projected to expand at a rapid pace in the coming years. This is due to an increase in geriatric population in China and Japan, rise in government participation in the prevention and control of arthritis, and improved distribution of joint pain injection in hospital and retail pharmacies in Asia Pacific.
Prominent players operating in the global joint pain injection market include Sanofi, Pfizer, Inc., Eli Lilly and Company, F. Hoffmann-La Roche Ltd, Allergan Inc., Anika Therapeutics, Inc., Alcon, Inc., Salix Pharmaceuticals Ltd., Seikagaku Corporation, GlaxoSmithKline plc, and Bristol-Myers Squibb Company.
MRR.BIZ has been compiled in-depth market research data in the report after exhaustive primary and secondary research. Our team of able, experienced in-house analysts has collated the information through personal interviews and study of industry databases, journals, and reputable paid sources.
The report provides the following information:
The main aim of the report is to:
MRR.BIZ is a leading provider of strategic market research. Our vast repository consists research reports, data books, company profiles, and regional market data sheets. We regularly update the data and analysis of a wide-ranging products and services around the world. As readers, you will have access to the latest information on almost 300 industries and their sub-segments. Both large Fortune 500 companies and SMEs have found those useful. This is because we customize our offerings keeping in mind the specific requirements of our clients.